LifeStance Health Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
TPG GP A, LLC sold 18.41M shares of LifeStance Health Group Inc (LFST) at $12.29/share, reducing its stake by 18.77%. LFST remains 22.55% of TPG's portfolio. LFST has a $4.82B market cap, a PE ratio of 97.46, and is deemed significantly overvalued by GuruFocus. The stock has gained 82.04% YTD but is down 36.65% since its 2021 IPO.
TPG GP A, LLC sold 18,409,705 indirectly-held shares of LifeStance Health Group, Inc. (LFST) at $12.29 ($226.26M total) on 2026-09-11. Filed jointly with COULTER JAMES G (10% owner) and WINKELRIED JON (10% owner).
LifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On September 9, 2026, LifeStance Health Group, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) by and among the Company, Barclays Capital Inc. (the “ Underwriter ”), and the selling stockholders named in Schedu
Over the past 7 days, AlphAI's AI scored 1 news story mentioning LFST (LifeStance Health Group, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent LFST coverage spans financial news, insider activity and corporate actions.
In the last 30 days, LFST insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($226.8M). The most active reporter was Paunovich Vukasin, Chief Technology Officer, with 1 filing.
Large institutional sell may pressure LFST price and signal reduced confidence.
Large insider sale may signal reduced confidence, potentially pressuring the stock.
The transaction is neutral to price; it reflects a share‑repurchase arrangement without cash inflow.
Strong earnings growth and bullish estimates may drive price appreciation.
The secondary offering could dilute existing shareholders but provides liquidity; the repurchase may offset some dilution.
AlphAI scores every news story that mentions LFST with an AI model for sentiment and relevance, and aggregates insider trades from LifeStance Health Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TPG GP A, LLC sold 18.41M shares of LifeStance Health Group Inc (LFST) at $12.29/share, reducing its stake by 18.77%. LFST remains 22.55% of TPG's portfolio. LFST has a $4.82B market cap, a PE ratio of 97.46, and is deemed significantly overvalued by GuruFocus. The stock has gained 82.04% YTD but is down 36.65% since its 2021 IPO.
2 min readTPG GP A, LLC sold 18,409,705 indirectly-held shares of LifeStance Health Group, Inc. (LFST) at $12.29 ($226.26M total) on 2026-09-11. Filed jointly with COULTER JAMES G (10% owner) and WINKELRIED JON (10% owner).
1 min readLifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On September 9, 2026, LifeStance Health Group, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) by and among the Company, Barclays Capital Inc. (the “ Underwriter ”), and the selling stockholders named in Schedu
1 min readZacks.com highlighted five companies with low debt-to-equity ratios: LifeStance Health (LFST) reported 26% revenue growth, Tutor Perini (TPC) won a $42M contract, News Corp (NWS) saw 11% revenue growth, Everus Construction (ECG) acquired Epsilon Industries, and HF Sinclair (DINO) finalized a pipeline joint venture. All five companies have positive earnings estimates and Zacks Rank #1 or #2.
3 min readLifeStance Health (LFST) announced a secondary offering of 22.25M shares by stockholders, with no proceeds to the company. LFST will repurchase 2M shares from the underwriter. Barclays is the sole underwriter. LFST stock traded between $4.77 and $13.15 in the past year, closing Tuesday at $12.80.
1 min readLifestance Health Group's stock is down 3.9% in pre-market trading after existing stockholders announced a secondary offering of 22.25 million shares. The company is not issuing new shares or receiving proceeds. A concurrent repurchase of 2 million shares is planned but contingent on the offering's completion. The broader market is also down, with the S&P 500, Dow Jones, and Nasdaq all declining. LFST is trading at $12.30, near its 52-week high of $13.15.
2 min readLifeStance Health Group's CTO, Paunovich Vukasin, sold 42,067 shares at an average price of $12.87, totaling $541,402. He now owns 205,379 shares. The sale occurred in multiple transactions between $12.86 and $12.905 per share, according to an SEC filing.
1 min readPaunovich Vukasin (Chief Technology Officer) sold 42,067 shares of LifeStance Health Group, Inc. (LFST) at $12.87 ($0.54M total) on 2026-09-02.
1 min readOmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.
2 min readLifestance Health Group (LFST) stock hit a 52-week high at $12.97, now trading at $13 with a $4.81B market cap. The stock surged 129.51% over the past year, driven by strong Q2 2026 earnings and raised full-year outlook. Revenue grew 26% to $435.35M, with adjusted EBITDA up 94% to $66M, according to the company.
2 min read
